Baseline characteristics and molecular testing of patients with IDH1-mutated cholangiocarcinoma: Initial results from the phase IIIb ProvIDHe study

被引：0
|
作者：
Rimassa, L. [1 ]
Bridgewater, J. A. [2 ]
Casadei-Gardini, A. [3 ]
Wilmink, H. [4 ]
Sim, H-W [5 ,6 ,7 ]
de Vos-Geelen, J. [8 ]
Mercade, T. Macarulla [9 ]
Malka, D. [10 ]
Gharbi, H. [11 ]
Robert, R. [11 ]
Sullivan, A. [12 ]
Vogel, A. [13 ]
机构：
[1] IRCCS Humanitas Res Hosp, Humanitas Canc Ctr, Rozzano, Italy
[2] UCL Canc Inst, Dept Med Oncol, Paul OGorman Bldg, London, England
[3] Univ Vita Salute San Raffaele, IRCCS San Raffaele Sci Inst Hosp, Dept Oncol, Milan, Italy
[4] Locatie Acad Med Ctr AMC, Amsterdam Univ Med Ctr UMC, Med Oncol, Amsterdam, Netherlands
[5] Kinghorn Canc Ctr, Dept Med Oncol, Sydney, NSW, Australia
[6] Univ New South Wales, Fac Med & Hlth, Sydney, NSW, Australia
[7] Univ Sydney, NHMRC Clin Trials Ctr, Darlinghurst, NSW, Australia
[8] Maastricht Univ Med Ctr MUMC, Dept Internal Med, Div Med Oncol, Maastricht, Netherlands
[9] VHIO Vall dHebron Inst Oncol, Med Oncol Dept, Barcelona, Spain
[10] Inst Gustave Roussy, Dept Med Oncol, Villejuif, France
[11] Servier, Global Med & Patient Affairs, Suresnes, France
[12] Servier Pharmaceut, Global Biometr, Boston, MA USA
[13] MHH, Hepatol Oncol, Hannover, Germany
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.159
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
138MO
引用
收藏
页码：S1457 / S1457
页数：1
相关论文
共 50 条
  • [1] Baseline characteristics and molecular testing of patients with IDH1-mutated cholangiocarcinoma: Initial results from the phase IIIb ProvIDHe study
    Rimassa, L.
    Bridgewater, J. A.
    Gardini, A. Casadei
    Wilmink, H.
    Sim, H-W.
    De Vos-Geelen, J.
    Mercade, T. Macarulla
    Malka, D.
    Gharbi, H.
    Robert, R.
    Sullivan, A.
    Vogel, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S236 - S236
  • [2] Baseline characteristics and molecular testing of Australian patients with IDH1 mutated cholangiocarcinoma: initial results from the phase IIIb ProvIDHe study
    Sim, H-W.
    McLachlan, S-A.
    Dean, A.
    Price, T. J.
    Eastgate, M.
    Rimassa, L.
    Mercade, T. Macarulla
    Malka, D.
    Gharbi, H.
    Robert, R.
    Sullivan, A.
    Vogel, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S1463 - S1463
  • [3] CHARACTERISTICS OF THE TUMOR MICROENVIRONMENT IN IDH1-MUTATED CHOLANGIOCARCINOMA PATIENTS FROM CLARIDHY TRIAL
    Saatcioglu, H. Duygu
    Valle, Juan
    Macarulla, Teresa
    Javle, Milind
    Oh, Do-Youn
    Goyal, Lipika
    Conway, Jake
    Iyer, Janani
    Najdawi, Fedaa
    Shah, Chintan
    Gliser, Camelia
    Pandya, Susan
    Daigle, Scott
    Abou-Alfa, Ghassan
    Kelley, Robin
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A576 - A577
  • [4] A perioperative study of Safusidenib in patients with IDH1-mutated glioma
    Cain, Sarah A.
    Topp, Monique
    Rosenthal, Mark
    Tobler, Robert
    Freytag, Saskia
    Best, Sarah A.
    Whittle, James R.
    Drummond, Katharine J.
    FUTURE ONCOLOGY, 2024, 20 (33) : 2533 - 2545
  • [5] Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1-mutated or IDH2-mutated solid tumours
    Molenaar, Remco J.
    Coelen, Robert J. S.
    Khurshed, Mohammed
    Roos, Eva
    Caan, Matthan W. A.
    van Linde, Myra E.
    Kouwenhoven, Mathilde
    Bramer, Jos A. M.
    Bovee, Judith V. M. G.
    Mathot, Ron A.
    Klumpen, Heinz-Josef
    van Laarhoven, Hanneke W. M.
    van Noorden, Cornelis J. F.
    Vandertop, W. Peter
    Gelderblom, Hans
    van Gulik, Thomas M.
    Wilmink, Johanna W.
    BMJ OPEN, 2017, 7 (06):
  • [6] EvIDHence study: Treatment patterns, duration of treatment and safety outcomes of patients with IDH1-mutated and wild-type cholangiocarcinoma
    Melisi, D.
    Lamarca, A.
    Blanc, J. F.
    Perkhofer, L.
    Gharbi, H.
    Robert, R.
    Sahai, V.
    ANNALS OF ONCOLOGY, 2024, 35 : S126 - S126
  • [7] A Phase Ib Clinical Trial of Metformin and Chloroquine in Patients with IDH1-Mutated Solid Tumors
    Khurshed, Mohammed
    Molenaar, Remco J.
    van Linde, Myra E.
    Mathot, Ron A.
    Struys, Eduard A.
    van Wezel, Tom
    van Noorden, Cornelis J. F.
    Kluempen, Heinz-Josef
    Bovee, Judith V. M. G.
    Wilmink, Johanna W.
    CANCERS, 2021, 13 (10)
  • [8] A phase II study of olaparib and durvalumab in patients with IDH-mutated cholangiocarcinoma
    Tsang, Erica S.
    O'Kane, Grainne M.
    Knox, Jennifer J.
    Chen, Eric X.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies
    Lachowiez, Curtis A.
    Loghavi, Sanam
    Zeng, Zhihong
    Tanaka, Tomoyuki
    Kim, Yi June
    Uryu, Hidetaka
    Turkalj, Sven
    Jakobsen, Niels Asger
    Luskin, Marlise R.
    Duose, Dzifa Y.
    Tidwell, Rebecca S. S.
    Short, Nicholas J.
    Borthakur, Gautam
    Kadia, Tapan M.
    Masarova, Lucia
    Tippett, George D.
    Bose, Prithviraj
    Jabbour, Elias J.
    Ravandi, Farhad
    Daver, Naval G.
    Garcia-Manero, Guillermo
    Kantarjian, Hagop
    Garcia, Jacqueline S.
    Vyas, Paresh
    Takahashi, Koichi
    Konopleva, Marina
    DiNardo, Courtney D.
    BLOOD CANCER DISCOVERY, 2023, 4 (04): : 276 - 293
  • [10] Quantitative risk-benefit assessment of ivosidenib compared to placebo in patients with IDH1-mutated intrahepatic cholangiocarcinoma: Phase 3 ClarIDHy trial
    Valle, J.
    Abou-Alfa, G.
    Kelley, R.
    Lowery, M.
    Shroff, R.
    Bian, Y.
    Saint-Hilary, G.
    Liu, H.
    Teng, Z.
    Hua, Z.
    Gliser, C.
    Vogel, A.
    Javle, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S162 - S162
12345